{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:41:13Z","timestamp":1788892873229,"version":"build-2803163510"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Global Antibiotic Research and Development Partnership"},{"DOI":"10.13039\/501100000265","name":"UKRI | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N025989\/1"],"award-info":[{"award-number":["MR\/N025989\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>Antimicrobial resistance (particularly through extended-spectrum \u03b2-lactamase and aminoglycoside-modifying enzyme production) in neonatal sepsis is a global problem, particularly in low- and middle-income countries, with significant mortality rates. High rates of resistance are reported for the current WHO-recommended first-line antibiotic regimen for neonatal sepsis, i.e., ampicillin and gentamicin.<\/jats:p>","DOI":"10.1128\/aac.00293-21","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T12:07:29Z","timestamp":1620216449000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-3413","authenticated-orcid":true,"given":"Christopher A.","family":"Darlow","sequence":"first","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Docobo-Perez","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Farrington","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McEntee","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jimenez-Valverde","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-6123","authenticated-orcid":true,"given":"Silke","family":"Gastine","sequence":"additional","affiliation":[{"name":"Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwanthi","family":"Kolamunnage-Dona","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata M. A.","family":"de Costa","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Ellis","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[{"name":"Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, St. George\u2019s University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piddock","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership, Geneva, Switzerland"},{"name":"Antimicrobials Research Group, School of Immunity and Infection, Institute for Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4816","authenticated-orcid":true,"given":"Shampa","family":"Das","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-878X","authenticated-orcid":true,"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31002-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.14.139790"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70804-7"},{"key":"e_1_3_3_5_2","volume-title":"Antibiotic use for sepsis in neonates and children: 2016 evidence update.","author":"Fuchs A","year":"2016","unstructured":"Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. 2016. Antibiotic use for sepsis in neonates and children: 2016 evidence update. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_6_2","volume-title":"Pocket book of hospital care for children","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Pocket book of hospital care for children, 2nd ed. World Health Organization, Geneva, Switzerland.","edition":"2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30148-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1913-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3233\/NPM-1765"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180705"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3394-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-018-1176-x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5314"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01121-14"},{"key":"e_1_3_3_15_2","first-page":"331","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco WR","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331\u2013385.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_3_16_2","first-page":"5318","article-title":"Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-\u03b2-d-arabinofuranosylcytosine","volume":"50","author":"Greco WR","year":"1990","unstructured":"Greco WR, Park HS, Rustum YM. 1990. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-\u03b2-d-arabinofuranosylcytosine. Cancer Res 50:5318\u20135327.","journal-title":"Cancer Res"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0092-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.878648"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00749-17"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Anu K Esther K Dunn SJ Dance DA Newton PN Davong V Sointu M Pakkanen SH Andreas N Cristoph H Ann S Teemu K Jukka C Alan M. 2019. Real-time sampling of travelers shows intestinal colonization by multidrug-resistant bacteria to be a dynamic process with multiple transient acquisitions. bioRxiv 827915. doi:10.1101\/827915.","DOI":"10.1101\/827915"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00334-06"},{"key":"e_1_3_3_22_2","volume-title":"British national formulary online.","author":"Joint Formulary Committee","year":"2021","unstructured":"Joint Formulary Committee. 2021. British national formulary online. Royal Pharmaceutical Society, London, England."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.10.2.205"},{"key":"e_1_3_3_24_2","unstructured":"Drugs for Neglected Diseases. 2019. Intravenous and oral fosfomycin in hospitalised neonates with clinical sepsis (NeoFosfo). ClinicalTrials.gov identifier NCT03453177. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03453177."},{"key":"e_1_3_3_25_2","unstructured":"Drugs for Neglected Diseases. 2018. NeoAMR observational study in neonatal sepsis. ClinicalTrials.gov identifier NCT03721302. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721302."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0641-x"},{"key":"e_1_3_3_27_2","volume-title":"Assessment report: referral under article 31 of directive 2001\/83\/EC: fosfomycin-containing medicinal products. Procedure number EMEA\/H\/A-31\/1476.","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. 2020. Assessment report: referral under article 31 of directive 2001\/83\/EC: fosfomycin-containing medicinal products. Procedure number EMEA\/H\/A-31\/1476. European Medicines Agency, Amsterdam, Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fosfomycin-article-31-referral-assessment-report_en.pdf."},{"key":"e_1_3_3_28_2","volume-title":"Red book: 2018\u20132021 report of the Committee on Infectious Diseases","author":"Brady M","year":"2018","unstructured":"Brady M, Jackson M, Kimberlin D, Long S. 2018. Red book: 2018\u20132021 report of the Committee on Infectious Diseases, 31st ed. American Academy of Pediatrics, Itasca, IL.","edition":"31"},{"key":"e_1_3_3_29_2","unstructured":"EUCAST. 2020. Breakpoint tables for interpretation of MICs and zone diameters Version 10.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.005"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00752-15"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04955-14"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv451"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05826-11"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx289"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199704000-00009"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(74)80308-2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01099-07"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh158"},{"key":"e_1_3_3_41_2","unstructured":"Tillomed Laboratories. 2020. Amikacin 250 mg\/ml solution for injection\/infusion. https:\/\/www.medicines.org.uk\/emc\/product\/11189\/smpc#gref."},{"key":"e_1_3_3_42_2","unstructured":"Kent Pharma UK. 2021. Fomicyt 40 mg\/ml powder for solution for infusion. https:\/\/www.medicines.org.uk\/emc\/product\/11249\/smpc#gref."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.116.2.1079-1081.1973"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00790.x"},{"key":"e_1_3_3_45_2","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software.","author":"D\u2019Argenio DZ","year":"2009","unstructured":"D\u2019Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. https:\/\/bmsr.usc.edu\/files\/2013\/02\/ADAPT5-User-Guide.pdf."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","unstructured":"Cadwell J. 2012. The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepidemiol Drug Saf S1:7. doi:10.4172\/2167-1052.S1-007.","DOI":"10.4172\/2167-1052.S1-007"},{"key":"e_1_3_3_48_2","unstructured":"Hospira UK. 2015. Amikacin 250 mg\/ml injection. https:\/\/www.medicines.org.uk\/emc\/product\/3784\/smpc#gref."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01152.x"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02530.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.1.33"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.34.2.265"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/15.suppl_A.125"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825c4ba6"},{"key":"e_1_3_3_55_2","article-title":"PK\/PD of intravenous and oral fosfomycin in neonates with presumed serious bacterial Infection","author":"Kane Z","year":"2020","unstructured":"Kane Z, Gastine S, Williams P, Berkley JA, Ellis S, Correia E, Darlow C, Hope W, Sharland M, Standing JF. 2020. PK\/PD of intravenous and oral fosfomycin in neonates with presumed serious bacterial Infection, abstr 4568. Proc ECCMID 2020.","journal-title":"Proc ECCMID 2020"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13016"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00293-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00293-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:09:35Z","timestamp":1645484975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00293-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.00293-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00293-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00293-21"}}